Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

What happens when public primary care is ill-prepared to respond to non-communicable diseases: a mixed-method study of diabetes and hypertension care in urban Nepal.

Journal of global health·2026
Same author

An enhanced hypergraph CNN with adaptive focal loss for automated ECG heartbeat classification.

Scientific reports·2026
Same author

Co-creation, co-design or co-production? Reflections on the development of urban health systems implementation strategies to improve access and quality of primary healthcare services in Bangladesh, Ghana, Nepal and Nigeria.

Health research policy and systems·2026
Same author

New histopathological terminology for well-differentiated hepatocellular lesions in unusual clinico-pathological scenarios: HCA-like and FNH-like.

JHEP reports : innovation in hepatology·2026
Same author

Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease.

Alimentary pharmacology & therapeutics·2026
Same author

Editorial: Cholestasis Is an Important Marker for Evaluating Clinical Outcomes and Prognosis in Severe Burns and Critically Ill Patients.

Alimentary pharmacology & therapeutics·2026

関連する実験動画

Updated: Jun 16, 2026

The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
11:08

The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy

Published on: March 13, 2014

妊娠中の肝臓疾患 妊娠中の肝臓疾患

Deepak Joshi1, Andra James, Alberto Quaglia

  • 1Institute of Liver Studies, King's College Hospital, London, UK.

Lancet (London, England)
|February 18, 2010
PubMed
まとめ

妊娠に関連した肝疾患は稀であるが,母親と胎児に重大なリスクをもたらす. 早期診断と病原性に関する最新の研究は,肝機能不全の妊婦の治療結果を改善するために不可欠です.

科学分野:

  • 産婦人科と産婦人科を担当しています.
  • 肝臓病理学 肝臓病理学
  • 妊産婦・胎児医学について

背景:

  • 妊娠中の重度の肝疾患はまれですが,母と胎児の両方の健康に重大な危険性があります.
  • 妊娠に関連した肝臓疾患は,妊娠中の肝臓機能不全の主要な原因です.
  • 妊娠に関連した肝疾患と関連のない肝疾患の間に合った区別は,効果的な管理に不可欠です.

研究 の 目的:

  • 妊娠中に発生する肝臓疾患の総合的な概要を提供するため.
  • 妊娠に関連した肝疾患の基礎となる病原性メカニズムに関する知識を更新する.
  • これらの状態の管理のための現在の治療戦略を評価する.

主な方法:

  • 妊娠に関連した肝疾患に関する文献レビュー.
  • 病原性メカニズムの分析. 病原性メカニズムの分析.
  • 治療選択肢の評価.

主要な成果:

  • 妊娠に関連した肝疾患は,母体および胎児の死亡率の重要な原因です.
  • パトジェネシスの理解における進歩は,より良い臨床結果につながりました.
  • 診断と治療の戦略は,進化し続けています.

さらに関連する動画

Laparoscopic Left Liver Sectoriectomy of Caroli's Disease Limited to Segment II and III
04:41

Laparoscopic Left Liver Sectoriectomy of Caroli's Disease Limited to Segment II and III

Published on: February 27, 2009

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

関連する実験動画

Last Updated: Jun 16, 2026

The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
11:08

The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy

Published on: March 13, 2014

Laparoscopic Left Liver Sectoriectomy of Caroli's Disease Limited to Segment II and III
04:41

Laparoscopic Left Liver Sectoriectomy of Caroli's Disease Limited to Segment II and III

Published on: February 27, 2009

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

結論:

  • 効果的な管理には,迅速かつ正確な診断が必要です.
  • 病原性に関する継続的な研究は,母と胎児の生存率を改善するために不可欠です.
  • 診断と治療の総合的なアプローチが推奨されます.